key: cord-0878681-biakaw5h authors: KURA, K.; Ayabina, D.; Toor, J.; Hollingsworth, T. D.; Anderson, R. M. title: Disruptions to schistosomiasis programmes due to COVID-19: an analysis of potential impact and mitigation strategies date: 2020-10-27 journal: nan DOI: 10.1101/2020.10.26.20219543 sha: 50a4429c5581caf7da63d12cba418d8bacc3c9ba doc_id: 878681 cord_uid: biakaw5h Background: The 2030 goal for schistosomiasis is elimination as a public health problem (EPHP), with mass drug administration (MDA) of praziquantel to school-aged children (SAC) a central pillar of the strategy. However, due to COVID-19, many mass treatment campaigns for schistosomiasis have been halted with uncertain implications for the programmes. Method: We use mathematical modelling to explore how postponement of MDA and various mitigation strategies affect achievement of the EPHP goal for Schistosoma mansoni and S. haematobium. Results: In moderate and some high prevalence settings, the disruption may delay the goal by up to two years. In some high prevalence settings EPHP is not achievable with current strategies, and so the disruption will not impact this. Here, increasing SAC coverage and treating adults can achieve the goal. The impact of MDA disruption and the appropriate mitigation strategy varies according to the baseline prevalence prior to treatment, the burden of infection in adults and stage of the programme. Conclusions: Schistosomiasis MDA programmes in medium and high prevalence areas should restart as soon as is feasible, and mitigation strategies may be required in some settings. Transmission model 103 We adopt an age-structured deterministic model developed by Imperial College 104 London (ICL). 8, 22 This model has an individual based stochastic analogue 8,22 but the 105 mean derived from this model is identical to the deterministic model prediction. The 106 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted October 27, 2020. ; https://doi.org/10.1101/2020.10.26.20219543 doi: medRxiv preprint model incorporates treatment by MDA and is parameterised for S. mansoni and S. 107 haematobium with previously published data and estimated parameter values derived 108 from past epidemiological studies (supplementary Table S1 ). 17 The numerical simulations were run for a single community with a population size set 116 at 1000, assuming no migration. In our simulations, treatment is delivered at random 117 at each round i.e. no systematic non-adherers and no non-access to treatment 118 individuals. Acquired immunity is not taken into consideration. 24 To simulate moderate 119 and high baseline prevalence settings (for low and high adult burden of infection), the 120 intrinsic intensity of transmission, i.e. basic reproductive number (R0), is varied (higher 121 prevalence settings corresponding to higher R0 values). In our investigation, we consider moderate ( 10 − 50% baseline prevalence among 124 SAC) and high ( ≥ 50% baseline prevalence among SAC) prevalence settings prior to 125 MDA. 2,11 In addition to this, for S. mansoni we use two different age intensity profiles 126 (low and high adult burden of infection) to determine whether this would differentially 127 influence the impact of missing MDA. In the model, we implement MDA annually at a 128 75% coverage level of SAC only. 11 We simulate one MDA round being missed either 129 early or late (second or sixth round of MDA, respectively) into the programme. For all For each transmission setting and age profile (Figure 1) with 75% coverage and random compliance the EPHP goal is achieved after one 153 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted October 27, 2020. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted October 27, 2020. ; https://doi.org/10.1101/2020.10.26.20219543 doi: medRxiv preprint perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted October 27, 2020. ; https://doi.org/10.1101/2020.10.26.20219543 doi: medRxiv preprint achieve EPHP within a shorter time frame, higher coverage of SAC and treating adults 196 would be needed for this setting. These coverage levels can be determined by 197 collecting SAC and adult data once programmes resume. 17 In Figure 4D , it is shown 198 that once the MDA programme resumes, increasing the SAC coverage to 85% and 199 including 40% of adults for every MDA round, can achieve the goal by 2030. Table S2 ). For the high transmission setting with a high adult burden, 229 it is predicted that it may take more than three years for the SAC prevalence to get years for the elimination as a public health problem to be achieved ( Table 3 and Table 238 4). For lower moderate prevalence settings (i.e. just above 10% SAC prevalence), the 239 heavy-intensity prevalence in SAC may be less than 1% before the start of the 240 treatment. Therefore, EPHP goal is met without any MDA intervention. Missing the 241 second round of MDA (Table 3) , will require up to one additional year to achieve the 242 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in where it takes longer than two years to achieve EPHP, a one year delay is also 256 expected when the programme is reintroduced at the previous coverage level after 257 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted October 27, 2020. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in However, care should be taken when deciding to stop MDA after EPHP has been 308 achieved as there will be a risk of resurgence/bounce back. This is because the overall 309 prevalence might still be high, so that infection persists, despite the heavy-intensity 310 prevalence in SAC being reduced to less than 1%. 26 Additionally, it is predicted that it 311 takes longer for the SAC prevalence to catch-up to what would have been achieved 312 by full MDA rounds, than it takes for the heavy-intensity prevalence. In this study, we assume that control programmes will return to their pre-COVID-19 314 effectiveness within one year, but this might not be feasible for various reasons. It is important to note one important caveat on the predictions made in this study. It 332 has been assumed that for a fixed MDA coverage level, treatment is at random in the 333 population. This may not be the case, as persistent non-adherers to treatment (due to 334 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted October 27, 2020. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted October 27, 2020. ; https://doi.org/10.1101/2020.10.26.20219543 doi: medRxiv preprint Advances in epidemiology survey methodology and 419 techniques in schistosomiasis A simple device for quantitative stool thick-422 smear technique in Schistosomiasis mansoni Bench Aids for the Diagnosis of Intestinal Parasites Achieving Elimination as a Public Health Problem for 428 When Is Community-Wide 429 Treatment Required? Modelling the impact of a 432 Schistosoma mansoni vaccine and mass drug administration to achieve 433 morbidity control and transmission elimination Policy implications of the potential use of a novel vaccine to 437 prevent infection with Schistosoma mansoni with or without mass drug 438 administration WHO issues interim guidance for implementation of NTD 441 programmes Helminth Infections of Humans: Mathematical Models The design of schistosomiasis monitoring and 454 evaluation programmes: The importance of collecting adult data to inform 455 treatment strategies for Schistosoma mansoni Acquired immunity 458 and epidemiology of Schistosoma haematobium WHO | New agreement expands access to schistosomiasis treatment for 461 millions Insights from quantitative and mathematical modelling on the proposed WHO 464 2030 goal for schistosomiasis The Geshiyaro Project: A study 468 protocol for developing a scalable model of interventions for moving towards the 469 interruption of the transmission of soil-transmitted helminths and schistosome 470 infections in the Wolaita zone of Ethiopia. Parasites and Vectors